Aiming for the cure in myeloma: Putting our best foot forward Review
| Authors: | Bar, N.; Firestone, R. S.; Usmani, S. Z. |
| Review Title: | Aiming for the cure in myeloma: Putting our best foot forward |
| Abstract: | Frontline therapy for multiple myeloma (MM) is evolving to include novel combinations that can achieve unprecedented deep response rates. Several treatment strategies exist, varying in induction regimen composition, use of transplant and or consolidation and maintenance. In this sea of different treatment permutations, the overarching theme is the powerful prognostic factors of disease risk and achievement of minimal residual disease (MRD) negativity. MM has significant inter-patient variability that requires treatment to be individualized. Riskadapted and response-adapted strategies which are increasingly being explored to define the extent and duration of therapy, and eventually aim for functional curability. In addition, with T-cell redirection therapies rapidly revolutionizing myeloma treatments, the current standard of care for myeloma will change. This review analyzes the current relevant literature in upfront therapy for fit myeloma patients and provides suggestions for treatment approach while novel clinical trials are maturing. |
| Keywords: | multiple myeloma; patient-reported outcomes; therapy; stem-cell transplantation; disease; induction; open-label; cure; minimal residual; diagnosed multiple-myeloma; low-dose dexamethasone; upfront therapy; high -risk disease; daratumumab plus lenalidomide; high-risk myeloma; eligible patients |
| Journal Title: | Blood Reviews |
| Volume: | 62 |
| ISSN: | 0268-960X |
| Publisher: | Churchill Livingstone |
| Date Published: | 2023-11-01 |
| Start Page: | 101116 |
| Language: | English |
| ACCESSION: | WOS:001133872600001 |
| DOI: | 10.1016/j.blre.2023.101116 |
| PROVIDER: | wos |
| PUBMED: | 37596172 |
| Notes: | Review -- 101116 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work